跳至主要内容
临床试验/NCT00541073
NCT00541073已完成2 期

Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma

Centre Oscar Lambret2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2007年6月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
2
主要终点
Individual dosage-adapted protocol

研究概览

简要总结

RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and vitamin B12 may kill more tumor cells.

PURPOSE: This phase II clinical trial is studying how well giving pemetrexed together with cisplatin and vitamin B12 works in treating patients with mesothelioma of the chest that cannot be removed by surgery.

详细描述

OBJECTIVES:

Primary

  • Define an individually adapted (by dosage) protocol of pemetrexed disodium, cisplatin, and vitamin B12 in patients with unresectable pleural mesothelioma.

Secondary

  • Determine the relationship between pharmacokinetic and pharmacodynamic parameters (hematologic and nonhematologic).
  • Analyze the inter-individual pharmacokinetic variations and the influence of the covariables on the pharmacokinetics of pemetrexed disodium.
  • Analyze the impact of pharmacogenetic (MTHFR, TS, GSTpi, ERCC1, XPD) variations on the toxicity of pemetrexed disodium.
  • Validate a strategy of adapting dosage.

研究设计

研究类型
Interventional
分配方式
Non Randomized
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Individual dosage-adapted protocol

次要结局

  • Relationship between pharmacokinetic and pharmacodynamic parameters
  • Pharmacokinetics
  • Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Pemetrexed, Cisplatin, and Vitamin B12 in Treating... | 临床试验